These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8391242)

  • 41. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma.
    Dalquen P; Sauter G; Torhorst J; Schultheiss E; Jordan P; Lehmann S; Solèr M; Stulz P; Mihatsch MJ; Gudat F
    J Pathol; 1996 Jan; 178(1):53-8. PubMed ID: 8778317
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of tumor deoxyribonucleic acid content in surgically resected small-cell carcinoma of lung.
    Carey FA; Prasad US; Walker WS; Cameron EW; Lamb D; Bird CC
    J Thorac Cardiovasc Surg; 1992 Jun; 103(6):1214-7. PubMed ID: 1317930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma.
    Raybaud H; Fortin A; Bairati I; Morency R; Monteil RA; Têtu B
    Int J Oral Maxillofac Surg; 2000 Feb; 29(1):36-41. PubMed ID: 10691142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma.
    Volm M; Hahn EW; Mattern J; Müller T; Vogt-Moykopf I; Weber E
    Cancer Res; 1988 May; 48(10):2923-8. PubMed ID: 2834052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Flow cytometric DNA content and clinical outcome in patients with non-small cell lung cancer given postoperative radiation therapy.
    Yu J; Shaeffer J; Zhu A; Kuban DA; el-Mahdi AM; Philput CB
    Cytometry; 1993; 14(4):428-32. PubMed ID: 8390343
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Flow cytometric DNA and p53 analysis in superficially infiltrating bladder carcinoma.
    Vatne V; Maartmann-Moe H; Hoestmark J
    Anticancer Res; 1994; 14(6B):2735-8. PubMed ID: 7872710
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic relevance of altered pRb and p53 protein expression in surgically treated non-small cell lung cancer patients.
    Dworakowska D; Jassem E; Jassem J; Wiedorn KH; Boltze C; Karmoliński A; Dworakowski R; Skokowski J; Jaśkiewicz K; Bosse A; Czestochowska E
    Oncology; 2004; 67(1):60-6. PubMed ID: 15459497
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Evaluation of the prognostic significance of P53 mutation in patients with non-small cell lung cancer].
    Jassem E; Rosell R; Jassem J; Monzo M; Kobierska G; Badzio A; Roszkiewicz A; Skokowski J; Szulc A
    Pneumonol Alergol Pol; 1998; 66(5-6):290-6. PubMed ID: 9857649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Contribution of flow cytometry in the prognostic evaluation of non-small-cell lung cancers. Review of the literature].
    Jeanfaivre T; Chassevent A; Larra F; Tuchais E
    Bull Cancer; 1994 Jul; 81(7):605-9. PubMed ID: 7742603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic value of flow cytometrically determined DNA-ploidy, intracellular pH and esterase activity of non-small cell lung carcinomas.
    Liewald F; Sunder-Plassmann L; Dienemann H; Kahle H; Wulf G; Valet G
    Anal Cell Pathol; 1992 Mar; 4(2):103-14. PubMed ID: 1312857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The importance of heterogeneity and of multiple site sampling in the prospective determination of deoxyribonucleic acid flow cytometry.
    Stipa S; Danesi DT; Modini C; Cicconetti F; Mauro F; Schillaci A; Mecozzi A; Nicolanti V; Stipa F; Mancini M
    Surg Gynecol Obstet; 1993 May; 176(5):427-34. PubMed ID: 8386859
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prognostic value of P53 protein in cells of non-small cell lung cancer].
    Jassem E; Góźdź S; Badzio A; Kobierska G; Skokowski J; Damps I; Urbaniak A; Jassem J
    Pneumonol Alergol Pol; 2000; 68(7-8):327-35. PubMed ID: 11200747
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Flow cytometry as a tool for the prognostic assessment of patients with lung and ovarian carcinomas.
    Volm M; Drings P; Kleine W; Mattern J
    Strahlenther Onkol; 1987 Dec; 163(12):791-4. PubMed ID: 2827331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Flow cytometric analysis of c-myc oncoprotein in non-small-cell lung carcinoma: comparison with immunohistochemical results.
    De Santis L; Mangili F; Sassi I; Di Rocco M; Rossi C; Cantaboni A
    Anal Cell Pathol; 1995 Apr; 8(3):247-57. PubMed ID: 7547497
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer.
    Passlick B; Izbicki JR; Häussinger K; Thetter O; Pantel K
    J Thorac Cardiovasc Surg; 1995 Jun; 109(6):1205-11. PubMed ID: 7776684
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synchronous lung cancers defined by deoxyribonucleic acid flow cytometry.
    Ichinose Y; Hara N; Ohta M
    J Thorac Cardiovasc Surg; 1991 Sep; 102(3):418-24. PubMed ID: 1652669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Di Carlo L; Semeraro A; Daddi G; Darwish S; Stocchi L; Tofanetti FR; Bellezza G; Sidoni A; Tognellini R; Crinò L; Tonato M
    Tumori; 2008; 94(3):398-405. PubMed ID: 18705409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer.
    Filderman AE; Silvestri GA; Gatsonis C; Luthringer DJ; Honig J; Flynn SD
    Am Rev Respir Dis; 1992 Sep; 146(3):707-10. PubMed ID: 1325749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.